215 related articles for article (PubMed ID: 31898803)
1. Second rebound-associated vertebral fractures after denosumab discontinuation.
Niimi R; Kono T; Nishihara A; Hasegawa M; Kono T; Sudo A
Arch Osteoporos; 2020 Jan; 15(1):7. PubMed ID: 31898803
[TBL] [Abstract][Full Text] [Related]
2. Rebound-associated vertebral fractures after discontinuation of denosumab for the treatment of maxillitis.
Niimi R; Kono T; Nishihara A; Hasegawa M; Kono T; Sudo A
Osteoporos Int; 2018 Mar; 29(3):769-772. PubMed ID: 29230512
[TBL] [Abstract][Full Text] [Related]
3. Stopping Denosumab.
Lamy O; Stoll D; Aubry-Rozier B; Rodriguez EG
Curr Osteoporos Rep; 2019 Feb; 17(1):8-15. PubMed ID: 30659428
[TBL] [Abstract][Full Text] [Related]
4. [How to manage the rebound effect at denosumab discontinuation and avoid multiple vertebral fractures?].
Gonzalez Rodriguez E; Lamy O; Aubry-Rozier B; Stoll D; Uebelhart B
Rev Med Suisse; 2019 Apr; 15(647):831-835. PubMed ID: 30994986
[TBL] [Abstract][Full Text] [Related]
5. Severe Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: 9 Clinical Cases Report.
Lamy O; Gonzalez-Rodriguez E; Stoll D; Hans D; Aubry-Rozier B
J Clin Endocrinol Metab; 2017 Feb; 102(2):354-358. PubMed ID: 27732330
[TBL] [Abstract][Full Text] [Related]
6. Rebound-associated vertebral fractures after stopping denosumab: Report of four cases.
Dupont J; Laurent MR; Dedeyne L; Luyten FP; Gielen E; Dejaeger M
Joint Bone Spine; 2020 Mar; 87(2):171-173. PubMed ID: 31369866
[No Abstract] [Full Text] [Related]
7. Multiple Rebound-Associated Vertebral Fractures after Denosumab Discontinuation: Is Prompt Antiresorptive Therapy Always Recommended,Even When the Risk of Fracture Seems Low? A Case Report.
Osella G; Puglisi S; Alì A; Reimondo G; Terzolo M
Endocr Metab Immune Disord Drug Targets; 2021; 21(12):2303-2306. PubMed ID: 34238202
[TBL] [Abstract][Full Text] [Related]
8. [Multiple Vertebral Fractures after Denosumab Discontinuation: How to Avoid Them?].
Lamy O; Gonzalez Rodriguez E; Stoll D; Aubry-Rozier B; Livio F
Praxis (Bern 1994); 2018 Jun; 107(12):649-654. PubMed ID: 29871576
[TBL] [Abstract][Full Text] [Related]
9. The Effect of Teriparatide for the Treatment of Multiple Spontaneous Clinical Vertebral Fractures after Discontinuation of Denosumab in a Female Patient with Rheumatoid Arthritis: A Case Report.
Mori Y; Izumiyama T; Mori N; Aizawa T
Tohoku J Exp Med; 2021 May; 254(1):57-61. PubMed ID: 34053968
[TBL] [Abstract][Full Text] [Related]
10. [The denosumab dilemma: to be stopped after 5 years or to be continued in patients with osteoporosis?].
Wolffenbuttel BHR; Abma EM; Appelman-Dijkstra NM
Ned Tijdschr Geneeskd; 2018 May; 162():. PubMed ID: 30040306
[TBL] [Abstract][Full Text] [Related]
11. Multiple severe vertebral fractures during the 3-month period following a missed dose of denosumab in a postmenopausal woman with osteoporosis previously treated with alendronate
.
Bandeira F; Torres G; Bandeira E; Duarte MB; Nóbrega AM; Bandeira L
Int J Clin Pharmacol Ther; 2019 Mar; 57(3):163-166. PubMed ID: 30663978
[TBL] [Abstract][Full Text] [Related]
12. Progression of Rebound-Associated Vertebral Fractures Following Denosumab Discontinuation Despite Reinstitution of Treatment: Suppressing Increased Bone Turnover May Not Be Enough.
Anastasilakis AD; Trovas G; Balanika A; Polyzos SA; Makras P; Tournis S
J Clin Densitom; 2021; 24(2):338-340. PubMed ID: 33218880
[TBL] [Abstract][Full Text] [Related]
13. Effect of follow-up raloxifene therapy after denosumab discontinuation in postmenopausal women.
Ha J; Kim J; Jeong C; Lim Y; Kim MK; Kwon HS; Song KH; Kang MI; Baek KH
Osteoporos Int; 2022 Jul; 33(7):1591-1599. PubMed ID: 35376989
[TBL] [Abstract][Full Text] [Related]
14. Twenty-four months of follow-up in women with rebound-associated vertebral fractures after discontinuation of denosumab: a single-centre case series.
Clifton Goldney D; Pelegrin C; Jerkovich F; Longobardi V; Gonzalez Rodriguez E; Zanchetta MB
Osteoporos Int; 2024 Jan; 35(1):165-171. PubMed ID: 37702746
[TBL] [Abstract][Full Text] [Related]
15. Long-term follow up after denosumab treatment for osteoporosis - rebound associated with hypercalcemia, parathyroid hyperplasia, severe bone mineral density loss, and multiple fractures: a case report.
Maugars Y; Guillot P; Glémarec J; Berthelot JM; Le Goff B; Darrieutort-Laffite C
J Med Case Rep; 2020 Aug; 14(1):130. PubMed ID: 32792004
[TBL] [Abstract][Full Text] [Related]
16. Rebound vertebral and non-vertebral fractures during denosumab interruption in a postmenopausal woman.
De Sousa SMC; Jesudason D
Clin Endocrinol (Oxf); 2019 Jan; 90(1):250-252. PubMed ID: 30269340
[No Abstract] [Full Text] [Related]
17. Magnetic resonance imaging has an advantage over conventional spine X-rays in the evaluation of rebound-associated vertebral fractures following denosumab discontinuation.
Anastasilakis AD; Evangelatos G; Makras P; Iliopoulos A
Endocrine; 2020 Sep; 69(3):516-518. PubMed ID: 32441026
[TBL] [Abstract][Full Text] [Related]
18. Elevated Bone Hardness Under Denosumab Treatment, With Persisting Lower Osteocyte Viability During Discontinuation.
Jähn-Rickert K; Wölfel EM; Jobke B; Riedel C; Hellmich M; Werner M; McDonald MM; Busse B
Front Endocrinol (Lausanne); 2020; 11():250. PubMed ID: 32499755
[TBL] [Abstract][Full Text] [Related]
19. Hypercalcemia upon denosumab withdrawal in primary hyperparathyroidism: a case report and literature review.
Camponovo C; Aubry-Rozier B; Lamy O; Gonzalez Rodriguez E
Osteoporos Int; 2020 Dec; 31(12):2485-2491. PubMed ID: 33057735
[TBL] [Abstract][Full Text] [Related]
20. Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment.
Anastasilakis AD; Yavropoulou MP; Makras P; Sakellariou GT; Papadopoulou F; Gerou S; Papapoulos SE
Eur J Endocrinol; 2017 Jun; 176(6):677-683. PubMed ID: 28283537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
